세계의 항체 생산 시장 : 제품별, 공정별, 최종 사용자별-기회 분석 및 산업 예측(2023-2032년)

The antibody production market was valued at $12.3 billion in 2022 and is projected to reach $29.4 billion by 2032, registering a CAGR of 9.1% from 2023 to 2032. Antibody production refers to the process by which specialized cells in the immune system, called B cells, produce antibodies in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Antibodies, also known as immunoglobulins, are Y-shaped proteins that specifically recognize and bind to antigens, which are unique molecules present on the surface of pathogens.

The process of antibody production begins when a B cell encounters an antigen that matches its specific receptor. This encounter triggers the activation and proliferation of the B cell, leading to the production of a large number of identical B cells, known as a clone. These activated B cells then differentiate into plasma cells, which are antibody-producing factories. Plasma cells secrete large quantities of antibodies into the bloodstream and other bodily fluids, where they can bind to and neutralize pathogens or mark them for destruction by other immune cells.

Factors driving the growth of the antibody production market include increase in prevalence of chronic diseases necessitating targeted therapies, advancements in biotechnology enhancing production efficiency and scalability, rising demand for monoclonal antibodies across therapeutic and research applications, and supportive government initiatives fostering research and development in antibody-based therapeutics. In addition, the biopharmaceutical industry is experiencing rapid growth due to increase in investments in research and development, as well as the rise in adoption of biologics-based therapies. Antibodies represent a significant portion of biopharmaceuticals, driving the demand for antibody production technologies and services.

Furthermore, government initiatives aimed at promoting biotechnology research and development, as well as funding support for biopharmaceutical companies and academic institutions, are fostering innovation and growth in the antibody production market. Public-private partnerships and grant programs are also contributing to the expansion of antibody-related research and commercialization efforts. For instance, in 2023, government initiatives for antibody production include the National Institutes of Health (NIH) supporting research to define mechanisms for establishing and maintaining immune responses, such as broadly neutralizing HIV antibodies to protect against HIV acquisition. Thus, rise in government initiatives for research and commercialization of antibodies further propels the market growth. Moreover, monoclonal antibodies (mAbs) have gained widespread acceptance in various therapeutic areas due to their high specificity and efficacy. The increasing number of approved monoclonal antibody drugs and their expanding applications in oncology, immunology, and other fields are driving the demand for antibody production and reagents.

However, the high costs associated with the development and production of antibodies present a significant restraint on the growth of the antibody production market. Antibody development involves a series of complex and resource-intensive processes, including antigen selection, hybridoma or phage display library generation, antibody screening, and optimization. These processes require specialized expertise, sophisticated equipment, and extensive laboratory resources, driving up development costs. Additionally, the production of therapeutic antibodies involves large-scale cell culture, purification, formulation, and quality control steps, all of which contribute to high production costs which may restrain market growth. On the other hand, the growing biopharmaceutical industry, coupled with increase in investments in research and development, presents opportunity to market growth.

The antibody production market is segmented on the basis of product, process, end user and region. By product, the market is bifurcated into instruments and consumables. The instruments segment is further categorized into bioreactors, chromatography systems, and filtration systems. By process, the market is divided into upstream processing and downstream processing. As per end user, it is segregated into pharmaceutical and biotechnology companies, CROs and CDMOs, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the antibody production market are Thermo Fisher Scientific Inc., Sartorius AG, Cellabcdmo, Agilent, Genetix Biotech Asia Pvt. Ltd., Cell Culture Company, Bio-Rad Laboratories, Inc, TECNIC, Merck KGaA, and Danaher Corporation. Key players have adopted acquisition as key developmental strategies to improve the product portfolio of the antibody production market.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antibody production market analysis from 2022 to 2032 to identify the prevailing antibody production market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the antibody production market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global antibody production market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By End User

• Pharmaceutical and Biotechnology Companies
• CROs and CDMOs
• Others

By Product

• Instruments
  • Type
  • Bioreactors
  • Chromatography Systems
  • Filtration Systems
• Consumables

By Process

• Upstream Processing
• Downstream Processing

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest Of La
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• Thermo Fisher Scientific Inc.
• Sartorius AG
• Cellabcdmo
• Agilent Technologies, Inc.
• Genetix Biotech Asia Pvt. Ltd.
• Cell Culture Company
• Bio-Rad Laboratories, Inc.
• TECNIC
• Merck KGaA
• Danaher Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: ANTIBODY PRODUCTION MARKET, BY PRODUCT

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Instruments
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. Instruments Antibody Production Market by Type
• 4.3. Consumables
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: ANTIBODY PRODUCTION MARKET, BY PROCESS

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Upstream Processing
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Downstream Processing
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: ANTIBODY PRODUCTION MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Pharmaceutical and Biotechnology Companies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. CROs and CDMOs
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: ANTIBODY PRODUCTION MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Product
  • 7.2.3. Market size and forecast, by Process
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Product
    • 7.2.5.1.2. Market size and forecast, by Process
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Product
    • 7.2.5.2.2. Market size and forecast, by Process
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Product
    • 7.2.5.3.2. Market size and forecast, by Process
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Product
  • 7.3.3. Market size and forecast, by Process
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Product
    • 7.3.5.1.2. Market size and forecast, by Process
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Product
    • 7.3.5.2.2. Market size and forecast, by Process
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Product
    • 7.3.5.3.2. Market size and forecast, by Process
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Product
    • 7.3.5.4.2. Market size and forecast, by Process
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Product
    • 7.3.5.5.2. Market size and forecast, by Process
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Product
    • 7.3.5.6.2. Market size and forecast, by Process
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Product
  • 7.4.3. Market size and forecast, by Process
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Product
    • 7.4.5.1.2. Market size and forecast, by Process
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Product
    • 7.4.5.2.2. Market size and forecast, by Process
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Product
    • 7.4.5.3.2. Market size and forecast, by Process
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Product
    • 7.4.5.4.2. Market size and forecast, by Process
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Product
    • 7.4.5.5.2. Market size and forecast, by Process
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Product
    • 7.4.5.6.2. Market size and forecast, by Process
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. Latin America
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Product
  • 7.5.3. Market size and forecast, by Process
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Product
    • 7.5.5.1.2. Market size and forecast, by Process
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Colombia
    • 7.5.5.2.1. Market size and forecast, by Product
    • 7.5.5.2.2. Market size and forecast, by Process
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Argentina
    • 7.5.5.3.1. Market size and forecast, by Product
    • 7.5.5.3.2. Market size and forecast, by Process
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest Of La
    • 7.5.5.4.1. Market size and forecast, by Product
    • 7.5.5.4.2. Market size and forecast, by Process
    • 7.5.5.4.3. Market size and forecast, by End User
• 7.6. Middle East and Africa
  • 7.6.1. Key market trends, growth factors and opportunities
  • 7.6.2. Market size and forecast, by Product
  • 7.6.3. Market size and forecast, by Process
  • 7.6.4. Market size and forecast, by End User
  • 7.6.5. Market size and forecast, by country
    • 7.6.5.1. Gcc
    • 7.6.5.1.1. Market size and forecast, by Product
    • 7.6.5.1.2. Market size and forecast, by Process
    • 7.6.5.1.3. Market size and forecast, by End User
    • 7.6.5.2. South Africa
    • 7.6.5.2.1. Market size and forecast, by Product
    • 7.6.5.2.2. Market size and forecast, by Process
    • 7.6.5.2.3. Market size and forecast, by End User
    • 7.6.5.3. North Africa
    • 7.6.5.3.1. Market size and forecast, by Product
    • 7.6.5.3.2. Market size and forecast, by Process
    • 7.6.5.3.3. Market size and forecast, by End User
    • 7.6.5.4. Rest Of Mea
    • 7.6.5.4.1. Market size and forecast, by Product
    • 7.6.5.4.2. Market size and forecast, by Process
    • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Thermo Fisher Scientific Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Sartorius AG
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Cellabcdmo
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Agilent Technologies, Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Genetix Biotech Asia Pvt. Ltd.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Cell Culture Company
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Bio-Rad Laboratories, Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. TECNIC
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Merck KGaA
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Danaher Corporation
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments